Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Ou Yamaguchi"'
Autor:
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and pr
Externí odkaz:
https://doaj.org/article/2b814dbbea994c51a018f1a190fff4f2
Autor:
Ou Yamaguchi, Keita Mori, Saori Takata, Kazuhiko Shibata, Kenichi Chikamori, Nozomu Kimura, Yoshiaki Nagai, Taku Nakagawa, Satoshi Igawa, Taishi Harada, Hiroshige Yoshioka, Hisashi Tanaka, Hitomi Nogawa, Hiroaki Satoh, Toshihiro Shiozawa, Kosuke Tsuji, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Thoracic Cancer, Vol 15, Iss 2, Pp 163-171 (2024)
Abstract Background The factors that predict the clinical response to ramucirumab plus docetaxel (RD) after first‐line chemoimmunotherapy are unresolved. We explored whether the therapeutic efficacy of prior chemoimmunotherapy could predict the out
Externí odkaz:
https://doaj.org/article/69b23a7a31d74e76959dd39356a3e58f
Autor:
Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100655- (2024)
Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who
Externí odkaz:
https://doaj.org/article/266c2a21ca60472ab272511e35e74652
Autor:
Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai, Ichiro Naruse, Hiroyuki Yamaguchi, Miki Itai, Kohei Taguchi, Megumi Uchida, Noriaki Sunaga, Toshitaka Maeno, Koichi Minato, Hiromi Tomono, Daiki Ogawara, Hiroshi Mukae, Yu Miura, Ayako Shiono, Atsuto Mouri, Hiroshi Kagamu, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are limited. Therefore, the pr
Externí odkaz:
https://doaj.org/article/136751bf535d4857a7d70d282fd7c6bf
Autor:
Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Kunihiko Kobayashi, Tomonori Kawasaki, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2950-2961 (2023)
Abstract Background Vascular endothelial growth factor (VEGF) has been identified as one of the resistant mechanisms to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, the relationship between the efficacy of osi
Externí odkaz:
https://doaj.org/article/fece6ef98b054e98ae461b7a3a7353f3
Autor:
Atsuto Mouri, Satoshi Watanabe, Takaaki Tokito, Yoshiaki Nagai, Yu Saida, Hisao Imai, Ou Yamaguchi, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu
Publikováno v:
Cancers, Vol 16, Iss 7, p 1409 (2024)
Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation followi
Externí odkaz:
https://doaj.org/article/a1dd98b83cd04202929d5213660b4788
Autor:
Daichi Fujimoto, Satoru Miura, Keisuke Tomii, Hiromitsu Sumikawa, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Toshihide Yokoyama, Takashi Kijima, Tetsuhiko Asao, Motohiro Tamiya, Atsushi Nakamura, Hiroshige Yoshioka, Takaaki Tokito, Shuji Murakami, Akihiro Tamiya, Hiroshi Yokouchi, Satoshi Watanabe, Ou Yamaguchi, Ryotaro Morinaga, Takayuki Jodai, Kentaro Ito, Yoshimasa Shiraishi, Yoshihito Kogure, Ryota Shibaki, Nobuyuki Yamamoto
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated
Externí odkaz:
https://doaj.org/article/d7954e13f28249d198db8ce843bb07a9
Autor:
Kyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Shin Yanagisawa, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka, Tamotsu Ishizuka, Koichi Minato, Satoshi Suda, Hiroshi Kagamu, Keita Mori, Nobuhiko Seki, Ichiei Kuji
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Purpose To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monotherapy in patients with
Externí odkaz:
https://doaj.org/article/561845a46d094745b5ca09fd534e42c6
Autor:
Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Kobayashi, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Aim Tumor-infiltrating lymphocytes (TILs) in the tumor and stroma are expected to accurately predict the efficacy of programmed death-1 (PD-1) blockade therapy. However, little is known about the prognostic significance of TILs in first-line
Externí odkaz:
https://doaj.org/article/51df83129f1f4f2b811f207816e4829f
Autor:
Ayako Shiono, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Hiroyuki Minemura, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Hiroki Takechi, Ou Yamaguchi, Atsuto Mouri, Kyoichi Kaira, Hirokazu Taniguchi, Koichi Minato, Hiroshi Kagamu
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 73-83 (2023)
Abstract Purpose The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). Methods
Externí odkaz:
https://doaj.org/article/7b714a5a6ae74295a24b9195992b391e